Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

Abstract:
PDS Biotechnology Corporation today announced that the company has been selected as a collaborator of the US National Cancer Institute's Nanotechnology Characterization Lab (NCL) to complete preclinical development of Versamune(TM)-HPV prior to filing of the Investigational New Drug Application. The NCL will perform selected physical, chemical and biological studies on behalf of the company at its facilities at the National Cancer Institute (NCI) in Frederick, Maryland. Dr. Frank Bedu-Addo, President of the Corporation stated that, "PDS Biotechnology Corporation's partnership with the NCL provides significant value to the company. The invaluable expertise of the NCL's scientists will provide the company with additional expert resources and technologies, and will facilitate rapid development of the product."

PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies

CINCINNATI, OH | Posted on November 6th, 2008

Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology Corporation was awarded in August 2008, a phase I SBIR grant by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-Melanoma to treat melanoma, which is the most aggressive form of skin cancer.

PDS Biotechnology Corporation's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen- presenting cells of the immune system and simultaneously acts a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).

####

About PDS Biotechnology Corporation
PDS Biotechnology Corporation (www.pdsbiotech.com) is a Cincinnati, Ohio-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

The NCL is a formal collaboration between the US National Cancer Institute, the US Food and Drug Administration (FDA) and the National Institute of Standards and Technologies (NIST) to rapidly advance promising cancer nanotechnology drugs through regulatory submissions with the FDA.

For more information, please click here

Contacts:
PDS Biotechnology Corporation
3130 Highland Avenue
Third Floor
Cincinnati, Ohio 45219
Tel: 513-475-6610
Fax: 513-221-1891

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Malvern’s Dr Alan Rawle talks TLAs in plenary lecture at Particulate Systems Analysis conference August 21st, 2014

Water window imaging opportunity: A new theoretical study elucidates mechanisms that could help in producing coherent radiations, ultimately promoting high-contrast imaging of biological samples August 21st, 2014

Nanotechnology Helps Production of Super Adsorbent Polymers August 21st, 2014

Graphene may be key to leap in supercapacitor performance August 20th, 2014

Laboratories

Promising Ferroelectric Materials Suffer From Unexpected Electric Polarizations: Brookhaven Lab scientists find surprising locked charge polarizations that impede performance in next-gen materials that could otherwise revolutionize data-driven devices August 18th, 2014

Research of Empa scientists on the cover of "Nature": Synthesis of structurally pure carbon nanotubes using molecular seeds August 7th, 2014

FEI Reports New Advances in Neuroscience in Collaboration with NIH: Using cryo-electron microscopy, researchers determine the structural mechanism of glutamate receptors – an important insight to the brain’s memory formation and learning August 4th, 2014

New Method Provides Nanoscale Details of Electrochemical Reactions in Electric Vehicle Battery Materials August 4th, 2014

Govt.-Legislation/Regulation/Funding/Policy

Success in Intracellular Imaging of Cesium Distribution in Plants Used for Cesium Absorption August 19th, 2014

Electrical engineers take major step toward photonic circuits: Team invents non-metallic metamaterial that enables them to 'compress' and contain light August 19th, 2014

Promising Ferroelectric Materials Suffer From Unexpected Electric Polarizations: Brookhaven Lab scientists find surprising locked charge polarizations that impede performance in next-gen materials that could otherwise revolutionize data-driven devices August 18th, 2014

Novel chip-based platform could simplify measurements of single molecules: A nanopore-gated optofluidic chip combines electrical and optical measurements of single molecules onto a single platform August 14th, 2014

Nanomedicine

Nanotechnology Helps Production of Super Adsorbent Polymers August 21st, 2014

Newly-Developed Nanobiosensor Quickly Diagnoses Cancer August 20th, 2014

Graphene rubber bands could stretch limits of current healthcare, new research finds August 19th, 2014

Interaction between Drug, DNA for Designing Anticancer Drugs Studied in Iran August 17th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanometrics CFO to Resign for New Job Opportunity August 8th, 2014

California Nanotechnologies Appoints Dr. Enrique Lavernia to the Board August 6th, 2014

ACS Biomaterials Science & Engineering™: Brand-new journal names editor July 29th, 2014

Organometallics welcomes new editor-in-chief: Paul Chirik, Ph.D. July 22nd, 2014

Alliances/Partnerships/Distributorships

Sunblock poses potential hazard to sea life August 20th, 2014

SouthWest NanoTechnologies Appoints Matteson-Ridolfi for U.S. Distribution of its SMW™ Specialty Multiwall Carbon Nanotubes August 13th, 2014

Could hemp nanosheets topple graphene for making the ideal supercapacitor? August 12th, 2014

On the frontiers of cyborg science August 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE